Pricing Log in Create free account
Saturday 17 October 2026 Export XRAY’s income statement to Excel — free account

DENTSPLY SIRONA Inc.

XRAY Healthcare Medical Instruments & Supplies

DENTSPLY SIRONA Inc.’s revenue for fiscal 2025 (year ended December 2025) was $3.7 billion, down 2.98% from fiscal 2024. In the quarter to June 2026, revenue fell 4.06%, EPS grew 181.8%, free cash flow grew 252.9% and total debt fell 10.0%, each against the same quarter a year earlier. Dividend growth for twenty-five consecutive years; insiders bought in the last twelve months.

8.57 0.26 −2.94%
Market cap
$1.8B
P/E
0.0×
Fwd P/E
27.0×
Dividend yield
1.87%
F-score
6/9
Altman Z
0.50
Beneish M
−3.03
Dividend safety
22/100
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total buys 1.74
Total sells 0.92
Totals in millions of $.
Dec 25 Mar 26 Jun 26 Sep 26
Buy 1 — — — 4 — — 6 — — — —
Sell — 1 — — — — — — — — — —
Insider Ownership 1.02%

Capital & Financial Ratios $m

Market Cap 1,760.00
Revenue 3,643.00
Net Income (547.00)
Free Cash Flow 147.00
Net Debt 1,757.00
Current Ratio 1.63 (at or above 1.5: strong)
Debt/Equity 1.48
P/E ratio 0.00
Fwd P/E 27.00
P/S ratio 0.47
P/B ratio 1.27
Past 5Y EPS Growth —
This Y EPS Growth (4.40%) (below 0%: weak)
Next Y EPS Growth (2.12%) (below 0%: weak)
Next Y revenue growth (2.96%) (below 0%: weak)
Next 5Y EPS Growth 0.80%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years
EV/Sales is 1.0×, against a ten-year median of 2.8×; over the ten years it ranged from 1.0× in 2026 to 5.1× in 2016.
P/S against its own 10 years 0.26%
10-year low 10-year high
P/B against its own 10 years 1.33%
10-year low 10-year high
EV/Sales against its own 10 years 0.26%
10-year low 10-year high
EV/FCF against its own 10 years 31.11%
10-year low 10-year high

Dividends

Payout Ratio —
Annual Dividend Rate 0.16
Annual Dividend Yield 1.87%
total individual payouts
2028 Powerpack
2027 Powerpack
2026 Powerpack
2025 0.64
0.16
0.16
0.16
0.16
2024 0.64
0.16
0.16
0.16
0.16
2023 0.56
0.14
0.14
0.14
0.14
2022 0.50
0.13
0.13
0.13
0.13
2021 0.43
0.10
0.11
0.11
0.11
2020 0.40
0.10
0.10
0.10
0.10
2019 0.38
0.09
0.09
0.10
0.10
2018 0.35
0.09
0.09
0.09
0.09
2017 0.44
0.09
0.09
0.09
0.09
0.09
2016 0.31
0.08
0.08
0.08
0.08
predictions special payouts not included in total or ratios

Assets vs Liabilities $m

2023 2024 2025 Q'26
Cash 334 272 326 239
Receivables 695 556 688 620
Inventory 624 564 642 665
Other — — — —
1,973 1,746 2,023 1,928
2023 2024 2025 Q'26
Payables 305 241 300 260
ST’ Debt — — — —
Other — — — —
1,425 1,589 1,343 1,185

Compound Annual Growth %

10y 5y 3y
Sales 3.24% 1.96% (2.10%)
Cash Flow (7.22%) (18.39%) (23.11%)
Earnings 0.00% 0.00% 0.00%
Book Value (5.42%) (22.95%) (29.43%)

Revenue $m

Mar Jun Sep Dec Year
’26 880 898 — — —
’25 879 936 904 961 3,680
’24 953 984 951 905 3,793
’23 978 1,028 947 1,012 3,965
’22 969 1,023 947 983 3,922
’21 1,026 1,062 1,040 1,103 4,231
’20 874 491 883 1,091 3,339
Fiscal quarters ending in the months shown.

Operating Cash Flow $m

Mar Jun Sep Dec Year
’26 40 99 — — —
’25 7 48 79 101 235
’24 25 208 141 87 461
’23 (21) 104 134 160 377
’22 93 173 109 142 517
’21 49 214 172 222 657
’20 (10) 174 221 264 649
Fiscal quarters ending in the months shown.

Free Cash Flow $m

Mar Jun Sep Dec Year
’26 (12) 60 — — —
’25 (12) 17 39 60 104
’24 (9) 157 97 36 281
’23 (60) 71 97 120 228
’22 49 132 77 110 368
’21 19 179 136 181 515
’20 (35) 161 199 237 562
Fiscal quarters ending in the months shown.

EPS $

Mar Jun Sep Dec Year
’26 (0.05) 0.18 — — —
’25 0.10 (0.22) (2.14) (0.74) (3.00)
’24 0.09 (0.02) (2.46) (2.16) (4.48)
’23 (0.09) 0.40 (1.25) 0.32 (0.62)
’22 0.30 0.34 (5.01) (0.07) (4.41)
’21 0.53 0.45 0.47 0.47 1.91
’20 (0.63) (0.44) 0.25 0.45 (0.38)
Fiscal quarters ending in the months shown.

Target Price Range

Analyst price targets

Recommendation Rating

2.7
1Buy 2 3Hold 4 5Sell

Ten years at a glance Fiscal years to December

Group Line 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 Trend 2026e 2027e 2028e
Price, $
Price, $ Low 53.43 52.54 33.93 36.63 31.58 48.13 26.48 26.27 17.21 9.85

Analyst estimates 2026–2028

Powerpack
High 65.83 68.98 68.47 60.15 60.87 69.54 58.70 43.24 37.60 20.60
People
People Employees 15,700 16,100 16,400 15,200 15,000 15,000 15,000 15,000 14,000 14,000
Revenue/emp, $m 0.24 0.25 0.24 0.26 0.22 0.28 0.26 0.26 0.27 0.26
Income, $m
Income, $m Revenue 3,745 3,993 3,986 4,022 3,339 4,231 3,922 3,965 3,793 3,680
Gross margin, % 53.42 54.80 51.88 53.80 49.60 55.47 54.23 52.61 51.62 50.00
EBT 441 (1,603) (958) 338 (50) 545 (1,055) (175) (936) (486)
EBT margin, % 11.77 (40.15) (24.03) 8.40 (1.50) 12.88 (26.90) (4.41) (24.68) (13.21)
Net income 431 (1,550) (1,011) 256 (73) 411 (950) (132) (910) (598)
Depreciation 276 1,970 1,420 323 491 346 1,515 634 1,122 877
Per share, $
Per share, $ Revenue 17.18 17.41 17.77 18.03 15.23 19.37 18.20 18.70 18.67 18.46
Earnings 1.97 (6.86) (4.51) 1.18 (0.38) 1.93 (4.41) (0.62) (4.48) (3.00)
Cash flow 2.58 2.62 2.23 2.86 2.96 3.01 2.40 1.78 2.27 1.18
Capex (0.56) (0.63) (0.80) (0.55) (0.40) (0.65) (0.69) (0.70) (0.89) (0.66)
Free cash flow 2.03 2.00 1.43 2.31 2.56 2.36 1.71 1.08 1.38 0.52
Book value 37.27 28.89 22.88 22.84 22.51 22.88 17.69 15.54 9.56 6.72
Shares, m 218 229 224 223 219 218 216 212 203 199
Valuation, ×
Valuation, × P/E 28.88 0.00 0.00 47.96 0.00 29.06 0.00 0.00 0.00 0.00
P/S 3.41 3.86 2.09 3.14 3.44 2.88 1.80 1.91 1.02 0.62
P/B 1.57 2.32 1.63 2.48 2.33 2.44 1.85 2.29 1.98 1.70
EV/Sales 3.71 4.18 2.41 3.39 3.90 3.25 2.17 2.27 1.36 1.08
EV/FCF 31.81 36.42 29.91 26.72 23.37 26.98 23.43 40.43 18.73 40.08
Cash, $m
Cash, $m Operating cash flow 563 602 500 639 649 657 517 377 461 235
Capex (121) (144) (179) (123) (87) (142) (149) (149) (180) (131)
Free cash flow 442 458 321 516 562 515 368 228 281 104
Balance, $m
Balance, $m Working capital 976 1,048 875 1,005 426 591 723 548 157 680
Total debt 1,511 1,612 1,565 1,433 1,978 1,913 1,826 1,796 1,586 2,015
Net debt 1,127 1,291 1,255 1,028 1,540 1,574 1,461 1,462 1,314 1,689
Shareholders’ equity 8,126 6,628 5,133 5,095 4,935 4,997 3,812 3,294 1,943 1,340
Returns, %
Returns, % ROA 5.39 (14.14) (10.61) 2.96 (0.81) 4.42 (11.25) (1.76) (13.87) (10.70)
ROIC 3.07 (12.33) (9.37) 3.60 (0.03) 5.78 (11.11) (1.12) (16.87) (8.71)
ROE 8.22 (21.01) (17.19) 5.01 (1.46) 8.28 (21.57) (3.72) (34.75) (36.43)
Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026

Charts ten years each

DENTSPLY SIRONA Inc. vs peers in Medical Instruments & Supplies (Q) = latest quarter vs a year earlier

Company Market cap P/E Fwd P/E Revenue growth (Q) EPS growth (Q) FCF growth (Q) Gross margin (Q) EBIT margin (Q) Compare
NVST Envista Holdings Corporation $3.8B 38.8× 24.4× +7.10% (above 0%: growing) +106.25% (above 0%: growing) +37.57% (above 0%: growing) 55.72% 10.99% Compare
PLSE Pulse Biosciences, Inc $3.3B — (loss-making) — (loss-making) +4,922.22% (above 0%: growing) n/m −45.39% (below 0%: shrinking) 37.10% (5,823.04%) Compare
WRBY Warby Parker Inc. $3.0B 334× 122× +9.81% (above 0%: growing) n/m −71.75% (below 0%: shrinking) 57.94% 1.34% Compare
ATRC AtriCure, Inc. $2.9B 259× 591× +12.83% (above 0%: growing) n/m −2.79% (below 0%: shrinking) 77.23% 6.29% Compare
LMAT LeMaitre Vascular, Inc. $1.9B 27.9× 31.5× +9.57% (above 0%: growing) +22.95% (above 0%: growing) −27.95% (below 0%: shrinking) 72.13% 28.98% Compare
XRAY DENTSPLY SIRONA Inc. $1.8B — (loss-making) 27.0× −4.06% (below 0%: shrinking) n/m +252.94% (above 0%: growing) 54.90% 9.13%
KMTS Kestra Medical Technologies, Ltd. $1.7B — (loss-making) — (loss-making) +59.88% (above 0%: growing) n/m −17.75% (below 0%: shrinking) 56.50% (121.59%) Compare
AZTA Azenta, Inc. $1.6B — (loss-making) — (loss-making) +12.04% (above 0%: growing) n/m −134.69% (below 0%: shrinking) 44.89% (2.59%) Compare
STAA STAAR Surgical Company $1.1B 304× 103× +111.04% (above 0%: growing) n/m +166.10% (above 0%: growing) 74.55% 10.80% Compare
Median of peers $2.4B 259× 103× +12.43% — −22.85% 57.22% 3.81%

All 55 Medical Instruments & Supplies stocks →

DENTSPLY SIRONA Inc. (XRAY) key facts

  • Concern: DENTSPLY SIRONA Inc.’s revenue for fiscal 2025 (year ended December 2025) was $3.7 billion, down 2.98% from fiscal 2024.
  • Concern: DENTSPLY SIRONA Inc. reported a net loss of $598.0 million, or a loss of $3.00 per share, for fiscal 2025.
  • DENTSPLY SIRONA Inc. (XRAY) is a Medical Instruments & Supplies company in the Healthcare sector, listed on Nasdaq.
  • As of October 16, 2026, XRAY traded at $8.57, a market capitalization of $1.8 billion.
  • Trailing earnings are negative, so a P/E ratio is not meaningful; the stock trades at 0.5× sales.
  • DENTSPLY SIRONA Inc. pays an annual dividend of $0.16 per share, a yield of 1.87%.
  • Return on equity was −36.4% and debt-to-equity 1.48.
  • Its Piotroski F-score is 6 out of 9 and its Altman Z-score is 0.50 (distress zone) for fiscal 2025.

Source: company filings (standardised) and stockrow calculations.

DENTSPLY SIRONA Inc. (XRAY) Latest News

No news at this impact. Lower the threshold for more.
stockrow.com/XRAY · Data as of Jun 30, 2026 · For information only; not investment advice. · © 2026 stockrow.com